Artiva Biotherapeutics Files 8-K on Corporate Governance
Ticker: ARTV · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1817241
| Field | Detail |
|---|---|
| Company | Artiva Biotherapeutics, Inc. (ARTV) |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Artiva Biotherapeutics filed an 8-K detailing leadership changes and governance matters.
AI Summary
Artiva Biotherapeutics, Inc. filed an 8-K on June 24, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides crucial updates on the company's leadership and governance structure, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 001-42179 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-3614316 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Artiva Biotherapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What specific changes were made regarding directors or officers?
The filing indicates reporting on the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and details are not provided in this excerpt.
Were any matters submitted to a vote of security holders?
Yes, the filing explicitly states 'Submission of Matters to a Vote of Security Holders' as an item reported.
What is the company's primary business sector?
Artiva Biotherapeutics, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, with SIC code 2836.
When was the earliest event reported in this filing?
The earliest event reported is dated June 24, 2025.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Artiva Biotherapeutics, Inc. (ARTV).